Student Authors
Yulian P. Ramirez; Jessica L. WeatherbeeUMass Chan Affiliations
Department of Biochemistry and Molecular PharmacologyDocument Type
Journal ArticlePublication Date
2013-01-01Keywords
angiogenesisautophagy
imidazotetrazine
MGMT
DNA repair
temozolomide
cancer stem cells
UMCCTS funding
Cancer Biology
Neoplasms
Therapeutics
Metadata
Show full item recordAbstract
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.Source
Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel). 2013 Nov 25;6(12):1475-506. doi: 10.3390/ph6121475. Link to article on publisher's website
DOI
10.3390/ph6121475Permanent Link to this Item
http://hdl.handle.net/20.500.14038/33342PubMed ID
24287492Related Resources
ae974a485f413a2113503eed53cd6c53
10.3390/ph6121475